| 陈萌,蒋志新,单其俊.钠-葡萄糖协同转运蛋白抑制剂治疗心力衰竭的研究进展[J].安徽医药,2021,25(12):2342-2345. |
| 钠-葡萄糖协同转运蛋白抑制剂治疗心力衰竭的研究进展 |
| Research progress of Sodium -glucose co-transporter 2 inhibitor in the treatment of heart failure |
| |
| DOI：10.3969/j.issn.1009-6469.2021.12.003 |
| 中文关键词: 心力衰竭 钠 -葡萄糖协同转运蛋白 2抑制剂 糖尿病 每搏输出量 |
| 英文关键词: Heart failure SGLT2 inhibitor Diabetes mellitus |
| 基金项目:国家自然科学基金项目( 81770333) |
|
| 摘要点击次数: 2079 |
| 全文下载次数: 691 |
| 中文摘要: |
| 钠-葡萄糖协同转运蛋白 2抑制剂( SGLT2i)是一类新型口服降糖药。大量临床研究表明: SGLT2i可通过非胰岛素依赖机制降低心血管疾病病死率和心力衰竭住院率，有望成为心力衰竭治疗的基础药物之一。本综述总结了 SGLT2i治疗心力衰竭的潜在机制和相关临床研究进展。 |
| 英文摘要: |
| Sodium -glucose co-transporter 2 inhibitor (SGLT2i) is a new type of oral hypoglycemic agent. A large number of clinicalstudies have shown that SGLT2i can reduce mortality of cardiovascular diseases and hospitalization rate of heart failure through thenon-insulin-dependent mechanism. It is expected to become one of the basic drugs for heart failure. This review summarizes possiblemechanism of SGLT2i in the treatment of heart failure and the related clinical advances. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
